Drugs / LTZ-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07121946 | Jan 2026 → Feb 2028 expected | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | LTZ Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-24 | LTZ Therapeutics, Inc. | Regulatory LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301 ltztherapeutics.com ↗
LTZ Therapeutics, an immunotherapy-focused biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for LTZ-301, a first-in-class myeloid engager immunotherapy intended to treat relapsed or refractory non-Hodgkin lymphoma (r/r NHL). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-24 | LTZ Therapeutics, Inc. | LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301 ltztherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTZ-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07121946 ↗ |
| Route | Intravenous | “LTZ-301 will be dosed IV” NCT07121946 ↗ |
| Target | CD79B | “targets B-cells via CD79B” NCT07121946 ↗ |